The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Alternative non-antibody scaffolds for molecular recognition
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bès, C., Troadec, S., Chentouf, M., Breton, H., Lajoix, A., Heitz, F., Gross, R., Plückthun, A., & Chardès, T. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.02.126 · Cited by 8
RetractedEngineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Potent antibody therapeutics by design
Carter, P. J. (2006) · Nature Reviews Immunology · doi:10.1038/nri1837 · Cited by 1,099
Antibody targeted drugs as cancer therapeutics
Schrama, D., Reisfeld, R. A., & Becker, J. C. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1957 · Cited by 768
Targeting and tracing antigens in live cells with fluorescent nanobodies
Rothbauer, U., Zolghadr, K., Tillib, S., Nowak, D., Schermelleh, L., Gahl, A., Backmann, N., Conrath, K., Muyldermans, S., Cardoso, M. C., et al. (2006) · Nature Methods · doi:10.1038/nmeth953 · Cited by 710
Engineering novel binding proteins from nonimmunoglobulin domains
Binz, H. K., Amstutz, P., & Plückthun, A. (2005) · Nature Biotechnology · doi:10.1038/nbt1127 · Cited by 676
High-affinity binders selected from designed ankyrin repeat protein libraries
Binz, H. K., Amstutz, P., Kohl, A., Stumpp, M. T., Briand, C., Forrer, P., Grütter, M. G., & Plückthun, A. (2004) · Nature Biotechnology · doi:10.1038/nbt962 · Cited by 656
Analyzing antibody specificity with whole proteome microarrays
Michaud, G. A., Salcius, M., Zhou, F., Bangham, R., Bonin, J., Guo, H., Snyder, M., Predki, P. F., & Schweitzer, B. I. (2003) · Nature Biotechnology · doi:10.1038/nbt910 · Cited by 277
Directed Evolution of High-Affinity Antibody Mimics Using mRNA Display
Xu, L., Aha, P., Gu, K., Kuimelis, R. G., Kurz, M., Lam, T., Lim, A. C., Liu, H., Lohse, P. A., Sun, L., et al. (2002) · Chemistry & Biology · doi:10.1016/s1074-5521(02)00187-4 · Cited by 251
Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains
Silverman, J., Lu, Q., Bakker, A., To, W., Duguay, A., Alba, B. M., Smith, R., Rivas, A., Li, P., Le, H., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1166 · Cited by 237
Cited by
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Beyond natural antibodies: the power of in vitro display technologies
Bradbury, A. R. M., Sidhu, S., Dübel, S., & McCafferty, J. (2011) · Nature Biotechnology · doi:10.1038/nbt.1791 · Cited by 545
Structural and thermodynamic analysis of the GFP:GFP‐nanobody complex
Kubala, M. H., Kovtun, O., Alexandrov, K., & Collins, B. M. (2010) · Protein Science · doi:10.1002/pro.519 · Cited by 400
Nucleic Acid and Peptide Aptamers: Fundamentals and Bioanalytical Aspects
Mascini, M., Palchetti, I., & Tombelli, S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201006630 · Cited by 374
A guide to: generation and design of nanobodies
Muyldermans, S. (2021) · The FEBS Journal · doi:10.1111/febs.15515 · Cited by 352
Dimitrov, D. S. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-921-1_1 · Cited by 347
Engineered protein scaffolds as next-generation antibody therapeutics
Gebauer, M., & Skerra, A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.627 · Cited by 341
Self-citationDARPins: A new generation of protein therapeutics
Stumpp, M. T., Binz, H. K., & Amstutz, P. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.04.013 · Cited by 254
Koide, A., Wojcik, J., Gilbreth, R. N., Hoey, R. J., & Koide, S. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.019 · Cited by 227
How mRNA therapeutics are entering the monoclonal antibody field
Van Hoecke, L., & Roose, K. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1804-8 · Cited by 205
Skerra, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06439.x · Cited by 176
Self-citationAdhiron: a stable and versatile peptide display scaffold for molecular recognition applications
Tiede, C., Tang, A. A. S., Deacon, S. E., Mandal, U., Nettleship, J. E., Owen, R. L., George, S. E., Harrison, D. J., Owens, R. J., Tomlinson, D. C., et al. (2014) · Protein Engineering, Design and Selection · doi:10.1093/protein/gzu007 · Cited by 163
Therapeutic Antibodies: Current State and Future Trends – Is a Paradigm Change Coming Soon?
Dimitrov, D. S., & Marks, J. D. (2009) · Methods in Molecular Biology™ · doi:10.1007/978-1-59745-554-1_1 · Cited by 132
Target-Binding Proteins Based on the 10th Human Fibronectin Type III Domain (10Fn3)
Koide, S., Koide, A., & Lipovšek, D. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-396962-0.00006-9 · Cited by 84
Metadata
- Authors
- Skerra, A.
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2007-08
- Volume
- 18
- Issue
- 4
- Pages
- 295-304
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W2065620086
- Cited by
- 300
- References
- 44
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.